Concepedia

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry

Lieneke F.M. Ariëns, Jorien van der Schaft, Lotte S. Spekhorst, Daphne S. Bakker, Geertruida L. E. Romeijn, T. Kouwenhoven, Marijke Kamsteeg, Angelique N. Voorberg, Albert J. Oosting, Ilona de Ridder,

Journal of the American Academy of Dermatology · 2020 · 91 citations · 22 references

DOIFull text

Open access

Concepts

References

22

Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use

A.Y. Finlay, Ghazala Khan · Clinical and Experimental Dermatology · 1994 · 5.5K citations

, , +8

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

Eric L. Simpson, Thomas Bieber, Emma Guttman‐Yassky et al. · New England Journal of Medicine · 2016 · 2K citations · Full text

, , +12

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

Mario Castro, Jonathan Corren, Ian Pavord et al. · New England Journal of Medicine · 2018 · 1.9K citations · Full text

, , +13

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham et al. · The Lancet · 2017 · 1.2K citations · Full text

, , +17

The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis

Jon M. Hanifin, Mark Thurston, Mitsuyoshi Omoto et al. · Experimental Dermatology · 2001 · 1.2K citations

, , +15